- Home
- Companies
- Synaffix BV
- Products
- GlycoConnect - Antibody-Drug ...
GlycoConnect - Antibody-Drug Conjugation Technology
GlycoConnect™ replaces the existing antibody glycan with a therapeutic payload. Synaffix has established a simple, yet powerful, clinical-stage platform technology enabling best-in-class ADCs, bispecific antibodies and the targeted delivery of various other therapeutic payloads, all without modifying the antibody sequence.
Building from of the well-understood cellular targeting abilities of antibodies, we combine the intrinsic efficiency of enzymes with the unique specificity of metal-free click chemistry to replace the native antibody glycan with a stably attached therapeutic payload.
Technology & How We Differentiate
- GlycoConnect™ enables best-in-class therapeutic efficacy and tolerability
- HydraSpace™ further differentiates efficacy and tolerability versus other site-specific ADC approaches
- toxSYN™ linker-payloads provide multiple options to maximize efficacy in light of tumor biology
- Proprietary DAR1 technology
- Protected by worldwide patent estate, consisting of 25+ patents
GlycoConnect™ Antibody-Drug Conjugation
Any antibody can be converted into a stably conjugated ADC in just a few days by modifying the native antibody glycan using our highly efficient enzymes and metal-free click chemistry approach.
Multiple independent experiments confirm that the native glycan position is likely one of the best for attaching ADC payloads to antibodies.